Medicare Locks In Drug Price Savings for 2026

Lower Prices on Ten Medications, Starting Now

Medicare beneficiaries began 2026 with access to reduced prices on ten high-cost prescription drugs, the first round of negotiated pricing made possible under federal prescription drug legislation passed in 2022. The medications include treatments for arthritis, blood clots, cancer, and diabetes. According to AARP, the negotiated prices took effect January 1 and must be made available through all Medicare Advantage prescription drug plans and standalone Part D drug plans. The projected savings for beneficiaries across the full year total approximately $1.5 billion, a figure that will continue to apply in future years as well.

The ten drugs subject to negotiation were selected based on their cost to Medicare and the extent to which lower-cost alternatives were not available. Every beneficiary enrolled in a qualifying plan should be able to access these medications at the negotiated rate. Because the negotiated prices are federally mandated, they are not optional for plan administrators - coverage must be made available regardless of which insurer runs the plan. Private insurers were given a window in early January to opt into covering GLP-1 weight-loss medications that were also added to the 2026 coverage framework, though eligibility for those drugs involves additional criteria.

Part D Cost Structure Changes

Beyond the drug pricing negotiations, the structure of Medicare’s prescription drug coverage has also changed in ways that affect out-of-pocket spending. The annual out-of-pocket cap under Part D increased from $2,000 to $2,100 for 2026, and the maximum deductible rose to $615. These adjustments reflect overall drug spending trends and apply across the Part D market. Some plans offer lower deductibles or no deductible at all, which makes the annual plan review during open enrollment an important financial decision for beneficiaries.

AARP also notes that the 2026 Medicare Plan Finder now includes provider network details for Medicare Advantage plans, making it easier for enrollees to confirm that their physicians and hospitals are included in a plan’s network before signing up. In prior years, that information required visiting each insurer’s website separately or working through an insurance broker. Beneficiaries who discover their coverage includes inaccurate network information within the first three months of enrollment will have a one-time opportunity to switch plans or return to Original Medicare.

What Beneficiaries Should Know About Insulin

One specific change affects insulin costs for Medicare Part D enrollees. For 2026, the insulin copay is capped at the lowest of three amounts: $35, 25 percent of the drug’s negotiated price, or 25 percent of Medicare’s new Maximum Fair Price. That calculation is designed to ensure that enrollees pay the least possible amount under their specific plan’s pricing structure. According to state-level Medicare guidance published through Minnesota’s Aging Pathways program, all CDC-recommended adult vaccines are also now covered with no cost sharing in 2026, including RSV, shingles, and Tdap vaccines, even when received out of network.

The Medicare Prescription Payment Plan, which allows monthly spreading of drug costs rather than paying larger amounts upfront, continues in 2026. Beneficiaries who were enrolled in this program in 2025 will be automatically re-enrolled unless they opt out. According to TheStreet, opt-out requests must be processed within three days of receiving notice.

The Financial Picture for 2026 Enrollees

The net financial effect of Medicare’s 2026 changes depends on what medications a beneficiary uses, which plan they are enrolled in, and what their income level is. The Part B premium - covering doctor visits and outpatient care - rose to $202.90 per month in January, a 9.7 percent increase from the $185 rate in 2025. For most Medicare enrollees, that premium is deducted directly from Social Security payments, which means the cost-of-living adjustment of 2.8 percent applied to Social Security in January is partially offset for many recipients by the premium increase.

Taking stock of all the moving parts - drug pricing changes, Part D structure adjustments, premium increases, and plan network updates - requires reviewing coverage annually rather than assuming the prior year’s plan remains optimal. AARP’s online Medicare resources and the official Medicare Plan Finder at Medicare.gov are the primary tools available for that review. For beneficiaries managing multiple prescriptions or considering a plan change, the January availability of negotiated drug prices makes this a useful moment to model out projected annual costs under different plan options.

References: What’s New in Medicare 2026 | Dave Ramsey, AARP Raise Red Flag on Medicare Changes Coming Soon